Noninvasive Screening for Early Evidence of Diabetes With SCOUT DS

The study will complete up to 500 subjects across 9 clinical sites to evaluate the precision and accuracy of SCOUT DS (Diabetes Screening) subjects at risk for type 2 diabetes. The study will involve up to two unique Scout devices at each clinical site. Each site will initially contain only a CS-1 (Commercial SCOUT 1) "A" for collection of data. As they become available, CS-1 "B"s operating with latest version of SCOUT software will be shipped to each site.

The NSEEDS study will enroll patients at-risk for type 2 diabetes who meet the study inclusion criteria (and do not meet one or more of the exclusion criteria) at approximately 9 clinical sites distributed across the United States. Eligible subjects must be at least 18 years old, not have an existing diagnosis of diabetes and, if less than 45 years old, must have a body mass index (BMI) ≥ 25 and at least one other risk factor for type 2 diabetes.

The data will be collected and a partial area under the receiver operator curve (pAUC) will be computed via the method of moments between the 20% and 50% false positive rates based on the first valid Scout "A" measurement for each patient. The impaired glucose tolerance status will be determined by the average of the two hour, post challenge plasma glucose samples measured at the central laboratory. This will be compared to 1000 bootstrap re-samplings of the calibration data pulling a cohort that matches that collected during this study. A test will be conducted to assure that the SCOUT performance lies within a 95% empirical confidence interval based on the bootstrap re-sampling.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Radiant Denver

Denver, Colorado, 80239, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age greater than or equal to 45 years;

Age 18 to 44 years and a BMI > 25 with one or more of the following diabetes risk factors:

Habitually physically inactive (less than 30 minutes of moderate physical activity most, if not all, days of the week)
Has a first-degree relative with type 2 diabetes
African American, Latino, Native American, Asian American, Pacific Islander
Has delivered a baby weighing > 9 lb or previously diagnosed with gestational diabetes
Hypertension (≥140/≥ 90 mmHg) or being treated for hypertension
HDL cholesterol level < 35 mg/dL and/or a fasting triglyceride level ≥ 250 mg/dL or being treated for dyslipidemia with medication
Has been previously diagnosed with Polycystic Ovary Syndrome (PCOS)
Had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 years
Conditions associated with insulin resistance such as severe obesity or acanthosis nigricans
History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease

Exclusion criteria

Prior participation in VeraLight studies: VL-2701, VL-2710, VL-2711, VL-2712 , or VL-2718
Diagnosed with any type of diabetes, including type 1 or 2
Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
Receiving any investigational treatment in the past 14 days
Psychosocial issues that interfere with an ability to follow study procedures
Conditions that cause secondary diabetes including Cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis
Taking glucose lowering medications*
Known to be pregnant (self reported)
Receiving dialysis or having known renal compromise
Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
Recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded
Current chemotherapy, or chemotherapy within the past 12 months
Receiving medications that fluoresce *
Prior bariatric surgery

Treatment and study plan

Primary outcomes

Validation of SCOUT DS algorithm, ROC performance equivalent to FPG, A1c for detection abnormal glucose tolerance.

Time frame: 6 months

The data will be collected and a partial area under the receiver operator curve (pAUC) will be computed via the method of moments between the 20% and 50% false positive rates based on the first valid Scout "A" measurement for each patient. The impaired glucose tolerance status will be determined by the average of the two hour, post challenge plasma glucose samples measured at the central laboratory. A test will be conducted to assure that the SCOUT performance lies within a 95% empirical confidence interval based on the bootstrap re-sampling.

Sponsors and collaborators

Lead sponsor

VeraLight, Inc.

Industry

Registry information

Acronym: NSEEDS

Important dates

Study start: 2011
Primary completion: 2011
Study completion: 2011
First posted: Jun 17, 2011
Registry last updated: Dec 4, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed